Welcome to our dedicated page for Global Innovative Platforms SEC filings (Ticker: GIPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global Innovative Platforms's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global Innovative Platforms's regulatory disclosures and financial reporting.
Global Innovative Platforms Inc. (GIPL) insider David A B Brown, a ten percent owner, purchased 2,500 shares of common stock on September 8, 2026, in an open-market brokerage transaction at $0.50 per share. The shares are held indirectly through the DAVID AB BROWN ROTH 401(K) PSP, which now holds 6,778,112 shares following this transaction.
Global Innovative Platforms Inc., a pre-revenue-stage animal health diagnostics company focused on breath analysis under its VetBreath Analytics brand, reported its first commercial revenues while remaining unprofitable for the quarter and nine months ended June 30, 2026.
The company generated $50,700 in revenue for the quarter and $187,200 for the nine months, all from a single contract with a leading global animal health company using its VetBreath Dx technology. Net losses were $241,611 for the quarter and $442,425 for the nine months, compared with losses of $211,818 and $483,635 in the prior-year periods. Cash and cash equivalents increased to $244,235, with total assets of $539,261 and minimal liabilities of $7,791, resulting in stockholders’ equity of $531,470. Operations were financed primarily through common stock issuances, including $620,000 raised in cash and 2,794,000 shares issued for services during the nine months.
Management discloses a going concern uncertainty due to limited revenue, accumulated deficit of $1,697,889, and dependence on raising additional capital. The business is also concentrated around a key Patent and Know-How License Agreement with Defiant Technologies, which requires milestone payments and a 3% royalty on net sales. Internal control over financial reporting is not effective, with material weaknesses in accounting expertise, segregation of duties, and spreadsheet controls. FINRA processed a Form 211 to allow priced quotations in the stock, but the existence of an active market is not assured.
Global Innovative Platforms Inc. director Campbell Elyssa Jacob reported a grant/award acquisition of 20,000 shares of Common Stock on June 30, 2026, at $0.12 per share. Following this non-derivative award, Jacob directly holds a total of 220,000 common shares.
Global Innovative Platforms Inc. reported that CEO, CFO and director Andrew Nicholas Brown received a grant/award acquisition of 250,000.0000 shares of common stock at $0.1200 per share on June 30, 2026. After this non-derivative transaction, he directly holds 11,060,554.0000 shares of the company’s common stock.
Global Innovative Platforms Inc. issued a shareholder update highlighting progress at VetBreath Analytics across funding, regulation, science, and partnerships. The company reports having enough capital to operate through the end of 2026 after completing a Regulation A offering in March 2026.
The update notes a 15c2-11 application submitted to FINRA on June 12, 2026, an eight-month heartworm study begun April 1, 2026, and development of four additional parasite breath signatures. Revenue for the six months ended March 31, 2026 was $136,500, supported by a collaboration generating about $15,000–$18,000 per month.
Global Innovative Platforms also expanded its Board and Strategic Advisory Board with experienced commercial, governance, and veterinary leaders, added new clinical development expertise, joined and won a Plug and Play incubator pitch competition, and launched a high-volume sample collection collaboration with Big Dog Ranch Rescue.
Global Innovative Platforms Inc. director and CEO/CFO Andrew Nicholas Brown reported two open-market purchases of common stock. He bought 250,000 shares on December 31, 2025 at $0.002 per share and another 250,000 shares on March 31, 2026 at $0.12 per share, for total purchases of 500,000 shares. After the most recent transaction, he directly owns 1,081,055 common shares.
Global Innovative Platforms Inc. reports that James C. Jones beneficially owns 92,812 shares of Common Stock, representing 14.99% of the class. The filing states the Reporting Person acquired the 92,812 shares in a purchase on 03/31/2021 and holds sole voting and dispositive power over those shares.
The disclosure lists the issuer's principal office in Maitland, Florida and provides the CUSIP 13767J104. The signature on the filing is dated 06/09/2026.
Global Innovative Platforms Inc. shareholder Jones James Carl, identified as a ten percent owner, filed a Form 4 that reports no insider transactions or holdings for the period covered. This appears to be an administrative insider ownership filing rather than a report of new share purchases, sales, or option exercises.
Global Innovative Platforms Inc. director Jones James Carl filed an initial Form 3 reporting his beneficial ownership. The filing shows indirect ownership of 1,171,012 shares of Common Stock held through the James C Jones Law Office. This is a disclosure of existing holdings rather than a new stock purchase or sale.
Global Innovative Platforms Inc. filed an initial insider ownership report showing that James Carl Jones is a ten percent owner. The filing lists indirect ownership of 92,812 shares of common stock held through the James C Jones 401(k) plan, with no specific buy or sell transaction reported.